Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via
Src kinase. This phosphorylation inhibits the binding of effector Raf while promoting the …

Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide
spectrum of cancers. While BRAF and MEK inhibitors are efficacious against BRAFV600E …

Deregulation of the RAS GTPase cycle due to mutations in the three RAS genes is
commonly associated with cancer development. Protein tyrosine phosphatase SHP2 …

The non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, has an
important role in signal transduction downstream of growth factor receptor signalling and …

The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by
PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine …

Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein
tyrosine phosphatase ubiquitously expressed mainly in the cytoplasm of several tissues …

Diagnostics and therapies have shown evident advances. Tumour surgery, chemotherapy
and radiotherapy are the main techniques in treat cancers. Targeted therapy and drug …

RAS mutations are frequent in human cancer, especially in pancreatic, colorectal and non-
small-cell lung cancers (NSCLCs),–. Inhibition of the RAS oncoproteins has proven difficult …

Src homology 2 (SH2)-containing protein tyrosine phosphatase 2 (SHP2), encoded by the
human PTPN11 gene, is a ubiquitously expressed protein tyrosine phosphatase (PTP) that …

New cancer therapies are likely to arise from an in-depth understanding of the signaling
networks influencing tumor initiation, progression and metastasis. We show a fundamental …